Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma
© 2020 British Society for Haematology and John Wiley & Sons Ltd..
Multiple myeloma (MM) tumour cells evade host immunity through a variety of mechanisms, which may potentially include the programmed cell death ligand-1 (PD-L1):programmed cell death protein-1 (PD-1) axis. This interaction contributes to the immunosuppressive bone marrow (BM) microenvironment, ultimately leading to reduced effector cell function. PD-L1 is overexpressed in MMBM and is associated with the resistance to immune-based approaches for treating MM. Ruxolitinib (RUX), an inhibitor of the Janus kinase (JAK) family of protein tyrosine kinases, is approved for myeloproliferative diseases. We investigated the effects of RUX alone or in combination with anti-MM agents on the expression of PD-L1 and T-cell cytotoxicity in MM. We showed that the expression of the PD-L1 gene was markedly increased in BM mononuclear cells from patients with MM with progressive disease versus those in complete remission. Furthermore, RUX treatment resulted in a concentration-dependent reduction of PD-L1 gene expression in the MM tumour cells cultured alone or co-cultured with stromal cells compared with untreated cells. The results also demonstrated that RUX increased MM cell apoptosis in the presence of interleukin-2-stimulated T cells to a similar degree as the treatment with anti-PD-1 or anti-PD-L1 antibodies. In summary, these results indicate that RUX can block PD-L1 expression resulting in augmentation of anti-MM effects of T cells.
| Errataetall: |
CommentIn: Br J Haematol. 2021 Feb;192(3):420-422. - PMID 33341927 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:192 |
|---|---|
| Enthalten in: |
British journal of haematology - 192(2021), 3 vom: 08. Feb., Seite 568-576 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Haiming [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.06.2021 Date Revised 26.02.2024 published: Print-Electronic CommentIn: Br J Haematol. 2021 Feb;192(3):420-422. - PMID 33341927 Citation Status MEDLINE |
|---|
| doi: |
10.1111/bjh.17282 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319067882 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319067882 | ||
| 003 | DE-627 | ||
| 005 | 20240229152443.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/bjh.17282 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1306.xml |
| 035 | |a (DE-627)NLM319067882 | ||
| 035 | |a (NLM)33341940 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Haiming |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.06.2021 | ||
| 500 | |a Date Revised 26.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Br J Haematol. 2021 Feb;192(3):420-422. - PMID 33341927 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 British Society for Haematology and John Wiley & Sons Ltd. | ||
| 520 | |a Multiple myeloma (MM) tumour cells evade host immunity through a variety of mechanisms, which may potentially include the programmed cell death ligand-1 (PD-L1):programmed cell death protein-1 (PD-1) axis. This interaction contributes to the immunosuppressive bone marrow (BM) microenvironment, ultimately leading to reduced effector cell function. PD-L1 is overexpressed in MMBM and is associated with the resistance to immune-based approaches for treating MM. Ruxolitinib (RUX), an inhibitor of the Janus kinase (JAK) family of protein tyrosine kinases, is approved for myeloproliferative diseases. We investigated the effects of RUX alone or in combination with anti-MM agents on the expression of PD-L1 and T-cell cytotoxicity in MM. We showed that the expression of the PD-L1 gene was markedly increased in BM mononuclear cells from patients with MM with progressive disease versus those in complete remission. Furthermore, RUX treatment resulted in a concentration-dependent reduction of PD-L1 gene expression in the MM tumour cells cultured alone or co-cultured with stromal cells compared with untreated cells. The results also demonstrated that RUX increased MM cell apoptosis in the presence of interleukin-2-stimulated T cells to a similar degree as the treatment with anti-PD-1 or anti-PD-L1 antibodies. In summary, these results indicate that RUX can block PD-L1 expression resulting in augmentation of anti-MM effects of T cells | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a JAK1/2 inhibitor | |
| 650 | 4 | |a PD-L1 | |
| 650 | 4 | |a Ruxolitinib | |
| 650 | 4 | |a T-cell cytotoxicity | |
| 650 | 4 | |a multiple myeloma | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a B7-H1 Antigen |2 NLM | |
| 650 | 7 | |a Nitriles |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Pyrazoles |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 650 | 7 | |a ruxolitinib |2 NLM | |
| 650 | 7 | |a 82S8X8XX8H |2 NLM | |
| 650 | 7 | |a Janus Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.10.2 |2 NLM | |
| 700 | 1 | |a Li, Mingjie |e verfasserin |4 aut | |
| 700 | 1 | |a Ng, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Erin |e verfasserin |4 aut | |
| 700 | 1 | |a Bujarski, Sean |e verfasserin |4 aut | |
| 700 | 1 | |a Yin, Zhengyi |e verfasserin |4 aut | |
| 700 | 1 | |a Wen, Mingxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Hekmati, Tara |e verfasserin |4 aut | |
| 700 | 1 | |a Field, Dylan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jasper |e verfasserin |4 aut | |
| 700 | 1 | |a Nassir, Isabella |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Janna |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Justin |e verfasserin |4 aut | |
| 700 | 1 | |a Daniely, David |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Cathy S |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Ning |e verfasserin |4 aut | |
| 700 | 1 | |a Spektor, Tanya M |e verfasserin |4 aut | |
| 700 | 1 | |a Berenson, James R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of haematology |d 1955 |g 192(2021), 3 vom: 08. Feb., Seite 568-576 |w (DE-627)NLM000000396 |x 1365-2141 |7 nnns |
| 773 | 1 | 8 | |g volume:192 |g year:2021 |g number:3 |g day:08 |g month:02 |g pages:568-576 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/bjh.17282 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 192 |j 2021 |e 3 |b 08 |c 02 |h 568-576 | ||